泰莎基因治疗

最新新闻

• 评级变动
  Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/4/6
• 评级变动
  BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Taysha Gene Therapies (TSHA) and Abivax SA Sponsored ADR (ABVX)
  TipRanks · 2026/6/30
• 评级变动
  Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/5/22
• BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Citizens JMP Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/7/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。